School of Basic Medical Sciences, Xi’an Jiaotong University | China
Author Profile
Orcid ID
LINA CHEN: A LEADING EXPERT IN ENDOCRINE AND CARDIOVASCULAR PHARMACOLOGY 🌱
📚 EARLY ACADEMIC PURSUITS
Lina Chen began her academic journey in 1992 at Xi’an Medical University, where she pursued a Bachelor of Medicine in Preventive Medicine. Her commitment to pharmacology led her to Xi’an Jiaotong University, where she completed her MSc in Pharmacology (2003) and later, a PhD in the same field (2006). These formative years laid the foundation for her distinguished career in pharmacology and medical sciences.
🧪 PROFESSIONAL ENDEAVORS
After obtaining her PhD, Lina Chen worked as a Lecturer in the Department of Pharmacology at Xi’an Jiaotong University (2006-2013). Her academic journey continued with an Associate Professorship (2013-2017) and eventually to the position of Professor (2018-present). Her career was also enriched by an international collaboration as a Visiting Scholar at the University of Nebraska Medical Center in 2009-2010, strengthening her global research network.
Professor Chen is renowned for her work in endocrine and cardiovascular pharmacology, specifically focusing on the pathogenesis, drug screening, prevention, and treatment of diabetes and metabolic diseases. She has led numerous high-profile research projects, including national programs such as the National Major New Drug Development Project and the National Natural Science Foundation of China. Her research has a significant impact on understanding and combating chronic diseases, particularly in the context of Chinese and global health challenges.
🌍 IMPACT AND INFLUENCE
Professor Chen’s groundbreaking work has influenced both academic research and practical healthcare solutions. She has contributed extensively to medical literature, with over 80 published articles, including 40 SCI papers. Her 7 national invention patents showcase her innovation in pharmacological treatments and drug development, cementing her reputation as a thought leader in her field. Her work is integral to the development of novel drugs and therapeutic strategies.
📈 ACADEMIC CITATIONS AND PUBLICATIONS
With an impressive Citation Index of 831, Professor Chen’s research has been widely recognized within the scientific community. Her work has been published in top-tier journals and included in more than 40 books. Her contributions have earned her recognition as a key player in pharmacological research. Professor Chen has also been an editorial board member for several prestigious journals, influencing scientific publication and policy.
🏅 HONORS & AWARDS
- Second Prize of Science and Technology Progress from Shaanxi Province
- National Invention Patents (7 patents)
- Various Research Grants and Fellowships, including those from the National Natural Science Foundation of China and the Provincial Key Projects.
🌐 LEGACY AND FUTURE CONTRIBUTIONS
Professor Chen‘s career is characterized by her unwavering commitment to public health, groundbreaking research, and innovative contributions to pharmacology. Looking ahead, her ongoing research will continue to shape the landscape of diabetes treatment and cardiovascular health, providing new hope for millions worldwide. Her future contributions are expected to be instrumental in furthering both scientific discovery and the practical application of pharmacological therapies.
🌠 FINAL NOTE
Professor Lina Chen continues to advance the field of pharmacology with a focus on diabetes and cardiovascular diseases. Her research excellence and innovative drug developments promise to leave a lasting legacy in both academia and global healthcare. With a clear vision for the future, she remains a leading voice in the pursuit of medical solutions for metabolic diseases.
📑 NOTABLE PUBLICATIONS
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
- Journal: Molecular Medicine (Cambridge, Mass.)
- Date: 2023-09-28
- Authors: Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, Fan K, Liu J, Zhu Y, Wang Z et al.
Corrigendum to “Erythropoietin ameliorates cognitive deficits by improving hippocampal and synaptic damage in streptozotocin-induced diabetic mice” [Cellular Signalling 106 (2023) 110614].
- Journal: Cellular Signalling
- Date: 2023-09-09
- Authors: Yan W, Guo T, Liu N, Cui X, Wei X, Sun Y, Hu H, Chen L
Erythropoietin ameliorates cognitive deficits by improving hippocampal and synaptic damage in streptozotocin-induced diabetic mice.
- Journal: Cellular Signalling
- Date: 2023-09-06
- Authors: Yan W, Guo T, Liu N, Cui X, Wei X, Sun Y, Hu H, Chen L
Mollugin activates GLP-1R to improve cognitive dysfunction in type 2 diabetic mice.
- Journal: Life Sciences
- Date: 2023-08-21
- Authors: Wang Z, Cui X, Yan W, Liu N, Shang J, Yi X, Guo T, Wei X, Sun Y, Hu H et al.
Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion.
- Journal: Molecular and Cellular Endocrinology
- Date: 2023-07-24
- Authors: Shang J, Yan W, Cui X, Ma W, Wang Z, Liu N, Yi X, Guo T, Wei X, Sun Y et al.